Wegovy Weight-Loss Pill Arrives in Israel, Offering Oral Alternative
Translated & summarized from N12 by baba
The oral version of the Wegovy weight-loss drug, containing semaglutide, is now available by prescription at Israeli private pharmacies. It offers a daily pill alternative to the injectable form, eliminating the need for injections and refrigeration, though it may be slightly less effective. The treatment is for adults with obesity or overweight with related health conditions, requiring careful adherence to daily dosing instructions and medical consultation due to potential side effects like gastrointestinal issues and nutritional deficiencies.
The story in 6 lines · by baba
- The oral Wegovy weight-loss pill is now available by prescription in Israel.
- It offers a daily pill alternative to the injectable form, eliminating injection and refrigeration needs.
- The oral pill may be slightly less effective than the injectable Wegovy.
- It is intended for adults with a BMI of 30+ or 27+ with weight-related conditions.
- Proper daily intake requires fasting and specific timing to ensure absorption.
- Potential side effects include gastrointestinal issues and risk of nutritional deficiencies.
The oral version of the Wegovy weight-loss medication is set to become available this week at private pharmacies in Israel, requiring a doctor's prescription. This pill offers an alternative for individuals struggling with obesity who are hesitant about injections or find them inconvenient. It contains semaglutide, the same active ingredient as the injectable Wegovy, which mimics the GLP-1 hormone to increase satiety and reduce appetite.
Unlike the weekly injection, the pill must be taken daily under specific conditions to ensure proper absorption. Key advantages include the elimination of the need for injections and the convenience of not requiring refrigeration, making it easier for travelers. However, the oral form may be slightly less effective than the injectable version, and the choice between them should consider individual medical conditions, treatment response, and patient preferences.
The treatment is intended for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension or type 2 diabetes, according to European guidelines. David Ppo, Chairman of the Israel Pharmacists Association, advises that the decision to start the medication should be made in consultation with a physician who will assess overall health, pre-existing conditions, and current medications.
Proper administration involves taking the pill on an empty stomach after at least an eight-hour fast, with a small amount of water, and waiting at least 30 minutes before eating, drinking, or taking other oral medications. This strict regimen is crucial for the drug's absorption. Patients on regular morning medications should consult their doctor or pharmacist about timing.
Potential side effects are primarily gastrointestinal, including nausea, abdominal pain, diarrhea, vomiting, and constipation. Ppo emphasizes a gradual increase in dosage to help the body adjust. Significant or worsening side effects require medical attention, and severe abdominal pain could indicate pancreatitis. Vomiting and diarrhea can lead to dehydration and potentially kidney impairment. A less obvious risk is nutritional deficiencies due to reduced appetite and food intake.
